Allo-SCT treatment of diffuse

The journal of Clinical Oncology (J Clin Oncol) according to a study published online in the near future, autologous hematopoietic stem cell transplantation (ASCT) recurrence of diffuse large b-cell non-Hodgkin's Lymphoma (DLBCL) receiving allogeneic hematopoietic stem cell transplantation (allo-SCT) are valid, ASCT term mitigation and allo-SCT-sensitive best suited to take up the offer. Research search the European blood and marrow transplant group database of patient information between 1997-2006, incorporating ASCT DLBCL patients with recurrence and first allo-SCT. Other in a set of standards to accept allo-SCT &GE;18 years of age, and there is a human leukocyte antigen (HLA) sibling or unrelated combinations of the same type of Haploidentical donors. The results were included 101 patients (57 male, median age is 46 years old).　　Study on survival in patients with median follow-up time was 36 months. Results showed that 37 patients receiving myeloablative processing, 64 cases of patients accepted the reduced strength of pretreatment (RIC). 3 years non-recurrence and mortality (NRM) 28.2%[95% confidence intervals (CI) for 20%~39%], the relapse rate (RR) for 30.1% (95%CI 22%~41%), progress-free survival (PFS) rates for 41.7% (95%CI 32%~52%), overall survival (OS) rate was 53.8% (95%CI 44%~64%). Patients &GE;45 years of age (P=0.01) and after early ASCT (< 12 months) in patients with recurrent (P=0.01) NRM significantly increased. RR significantly elevated in patients with refractory (P=0.03). After the ASCT < recurrence and PFS reduce 12 month (P=0.03). RIC and lower PFS (P=0.1) and higher RR (P=0.1), but did not affect PFS and OS.　　Compatriots of the same study found no HLA and unrelated matched donors distribution above several study results are different. Related link: Allogeneic Stem-Cell Transplantation As Salvage Therapy for Patients With Diffuse Large B-Cell  Non-Hodgkin's Lymphoma Relapsing After an Autologous Stem-Cell Transplantation: An Analysis of the  European Group for Blood and Marrow Transplantation Registrywww.cmt.com.cn  

In patients with multiple scle

In the recently held United States Academy of Neurology (ANN) 2010 meeting, pointed out that, if multiple sclerosis (MS) terminates his nimotuzumab in patients with treatment, physicians should prepare candidates for treatment programmes to prevent disease recurrence and other complications.　　　Commentators said the United States that his beads monoclonal antibody drug users have three, in Europe, drug users have 58% of progressive multifocal leukoencephalopathy (PML). A recent small study shows that MS deactivated after he nimotuzumab in patients with no apparent adverse events, but it uses interferon or other drugs. Another study shows that take drugs without interferon, is quite a lot of MS patients with magnetic resonance imaging (MRI) detected during an inspection-related damage and disease may relapse after 60-90 days. www.cmt.com.cn  

Infant antibiotics increase th

Intestinal flora and inflammatory intestinal disease (IBD) pathogenesis-related. Baby was built on intestinal tract normal flora during an important period, antibiotic application at this stage will affect the intestinal normal bacterial flora of the building, but will affect the incidence of IBD?　　　Canada scholars report, application of antibiotics in infancy and children related to IBD risk is significantly stronger. The study included 264 participants, with 24 cases of children with, 240 were controlled. In 24 children, 15 cases of Crohn's disease, 9 cases of ulcerative colitis (UC).　　　Average age of diagnosis is 6.4 years. 1th year after these IBD in children with birth average of 2.2 antibiotic treatment, controlled by 0.9. 1th year of birth accepted at least 1 antibiotic treatment is diagnosed with IBD odds ratio was born 1th year after not receiving antibiotic therapy is 5.8 times. www.cmt.com.cn